AR052052A1 - Terapia de combinacion - Google Patents
Terapia de combinacionInfo
- Publication number
- AR052052A1 AR052052A1 ARP050105303A ARP050105303A AR052052A1 AR 052052 A1 AR052052 A1 AR 052052A1 AR P050105303 A ARP050105303 A AR P050105303A AR P050105303 A ARP050105303 A AR P050105303A AR 052052 A1 AR052052 A1 AR 052052A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination therapy
- hydrochlorothiazide
- telmisartan
- angiotensin
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion farmacéutica que comprende aproximadamente 80mg de telmisartano y aproximadamente 25mg de hidroclorotiazida, o aproximadamente 160mg de telmisartano y aproximadamente 50 mg de hidroclorotiazida, para el tratamiento de la hipertension en pacientes con una reduccion de la tension arterial insuficiente tras un tratamiento con un antagonista del receptor de angiotensina II, o una composicion farmacéutica de un antagonista del receptor de angiotensina II y una dosis de hidroclorotiazida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63706204P | 2004-12-17 | 2004-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052052A1 true AR052052A1 (es) | 2007-02-28 |
Family
ID=35589356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105303A AR052052A1 (es) | 2004-12-17 | 2005-12-16 | Terapia de combinacion |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1827424A1 (es) |
JP (1) | JP2008524136A (es) |
KR (1) | KR20070097511A (es) |
CN (1) | CN101080225A (es) |
AR (1) | AR052052A1 (es) |
AU (1) | AU2005315855A1 (es) |
BR (1) | BRPI0519656A2 (es) |
CA (1) | CA2589493A1 (es) |
EA (1) | EA200701159A1 (es) |
IL (1) | IL183944A0 (es) |
NO (1) | NO20072325L (es) |
PE (1) | PE20060768A1 (es) |
TW (1) | TW200637546A (es) |
UY (1) | UY29274A1 (es) |
WO (1) | WO2006063737A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
US8637078B2 (en) | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
SI2180882T1 (sl) † | 2007-10-19 | 2013-05-31 | Otsuka Pharmaceutical Co., Ltd. | Trdni matriksni farmacevtski pripravek |
EP2203158A4 (en) | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
CA2715350C (en) | 2008-03-19 | 2017-02-14 | Ratiopharm Gmbh | Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
PE20110551A1 (es) * | 2008-07-31 | 2011-09-02 | Takeda Pharmaceutical | Composicion farmaceutica solida que contiene un derivado de bencimidazol y un diuretico |
GB0822170D0 (en) * | 2008-12-04 | 2009-01-14 | Arrow Int Ltd | Telmisartan with diuretic formulations |
WO2010146187A2 (en) | 2009-06-19 | 2010-12-23 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
EP2448576A2 (en) * | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
WO2011002425A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgig Mahmut | Pharmaceutical composition increasing solubility and stability |
TR200906506A2 (tr) | 2009-08-24 | 2011-03-21 | Bi̇lgi̇ç Mahmut | Telmisartan içeren katı dozaj formları. |
WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
WO2014119767A1 (ja) * | 2013-01-31 | 2014-08-07 | 沢井製薬株式会社 | テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤 |
JP6422868B2 (ja) * | 2013-07-23 | 2018-11-14 | 第一三共株式会社 | 高血圧症の予防又は治療のための医薬 |
CN106562973A (zh) * | 2016-11-06 | 2017-04-19 | 成都先先先生物科技有限公司 | 一种抗高血压药物复方制剂 |
CN107501192A (zh) * | 2017-08-15 | 2017-12-22 | 中国科学院上海药物研究所 | 替米沙坦与氢***的共晶 |
CN108653227A (zh) * | 2018-08-09 | 2018-10-16 | 湖北舒邦药业有限公司 | 一种替米沙坦氢***片及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4229085C2 (de) * | 1992-09-01 | 1996-07-11 | Boehringer Mannheim Gmbh | Längliche, teilbare Tablette |
PT1854454E (pt) * | 2002-01-16 | 2014-01-09 | Boehringer Ingelheim Pharma | Método para a preparação de telmisartan amorfo |
-
2005
- 2005-12-09 JP JP2007545905A patent/JP2008524136A/ja active Pending
- 2005-12-09 KR KR1020077016354A patent/KR20070097511A/ko not_active Application Discontinuation
- 2005-12-09 EA EA200701159A patent/EA200701159A1/ru unknown
- 2005-12-09 EP EP05814002A patent/EP1827424A1/en not_active Withdrawn
- 2005-12-09 CA CA002589493A patent/CA2589493A1/en not_active Abandoned
- 2005-12-09 AU AU2005315855A patent/AU2005315855A1/en not_active Abandoned
- 2005-12-09 CN CNA2005800434334A patent/CN101080225A/zh active Pending
- 2005-12-09 BR BRPI0519656-6A patent/BRPI0519656A2/pt not_active Application Discontinuation
- 2005-12-09 WO PCT/EP2005/013224 patent/WO2006063737A1/en active Application Filing
- 2005-12-15 PE PE2005001465A patent/PE20060768A1/es not_active Application Discontinuation
- 2005-12-16 AR ARP050105303A patent/AR052052A1/es unknown
- 2005-12-16 TW TW094144909A patent/TW200637546A/zh unknown
- 2005-12-20 UY UY29274A patent/UY29274A1/es not_active Application Discontinuation
-
2007
- 2007-05-04 NO NO20072325A patent/NO20072325L/no not_active Application Discontinuation
- 2007-06-14 IL IL183944A patent/IL183944A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200637546A (en) | 2006-11-01 |
AU2005315855A1 (en) | 2006-06-22 |
PE20060768A1 (es) | 2006-09-29 |
WO2006063737A1 (en) | 2006-06-22 |
EP1827424A1 (en) | 2007-09-05 |
NO20072325L (no) | 2007-07-06 |
CN101080225A (zh) | 2007-11-28 |
IL183944A0 (en) | 2007-10-31 |
EA200701159A1 (ru) | 2007-12-28 |
KR20070097511A (ko) | 2007-10-04 |
CA2589493A1 (en) | 2006-06-22 |
BRPI0519656A2 (pt) | 2009-03-03 |
UY29274A1 (es) | 2006-07-31 |
JP2008524136A (ja) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052052A1 (es) | Terapia de combinacion | |
AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
ECSP099501A (es) | Formulaciones de dosis unitaria y métodos para el tratamiento de la trombosis con un inhibidor oral del factor xa | |
TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
AR046811A1 (es) | Formas de dosificacion oral de ziprasidona de liberacion sostenida | |
AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
AR062860A1 (es) | Combinaciones terapeuticas 482 | |
AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2011000625A1 (es) | Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida. | |
CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
AR034517A1 (es) | Formulacion farmaceutica | |
AR061446A1 (es) | Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico | |
MX2009011900A (es) | Curacion de herida diabetica. | |
CY1112269T1 (el) | Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος | |
AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
AR048370A1 (es) | Composicion para mejorar funciones cognitivas y la memoria | |
AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
CR9200A (es) | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos | |
CL2008003558A1 (es) | Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga. | |
AR034975A1 (es) | Metodo para el tratamiento del insomnio primario |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |